Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115697) titled 'The efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in resectable elderly NSCLC patients with stage IIA-IIIB' on Dec. 30, 2025.
Study Type: Observational study
Study Design:
Single arm
Primary Sponsor: The First Medical Center of Chinese PLA General Hospital
Condition:
Non-small cell lung cancer
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-01-01
Target Sample Size: One:50;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=278048
Published by HT Digital Content Services with permission from He...